

Takeshi Motohara

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6412108/publications.pdf>

Version: 2024-02-01

26
papers

2,245
citations

623734

14
h-index

580821

25
g-index

28
all docs

28
docs citations

28
times ranked

3672
citing authors

#	ARTICLE	IF	CITATIONS
1	Changes in HPV16/18 Prevalence among Unvaccinated Women with Cervical Intraepithelial Neoplasia in Japan: Assessment of Herd Effects following the HPV Vaccination Program. <i>Vaccines</i> , 2022, 10, 188.	4.4	2
2	Human papillomavirus vaccine effectiveness by age at first vaccination among Japanese women. <i>Cancer Science</i> , 2022, 113, 1428-1434.	3.9	6
3	Maternal thrombocytopenia precedes fetal death associated with COVID-19. <i>Journal of Obstetrics and Gynaecology Research</i> , 2022, 48, 1475-1479.	1.3	4
4	Fertility-sparing surgery for early-stage cervical cancer: A case series study on the efficacy and feasibility of cervical conization followed by pelvic lymphadenectomy. <i>Journal of Obstetrics and Gynaecology Research</i> , 2022, 48, 1444-1450.	1.3	3
5	The hallmarks of ovarian cancer stem cells and niches: Exploring their harmonious interplay in therapy resistance. <i>Seminars in Cancer Biology</i> , 2021, 77, 182-193.	9.6	38
6	Adipocyte-like signature in ovarian cancer minimal residual disease identifies metabolic vulnerabilities of tumor initiating cells. <i>JCI Insight</i> , 2021, 6, .	5.0	3
7	Angiopoietin-like protein 2 decreases peritoneal metastasis of ovarian cancer cells by suppressing anoikis resistance. <i>Biochemical and Biophysical Research Communications</i> , 2021, 561, 26-32.	2.1	12
8	Omental metastasis as a predictive risk factor for unfavorable prognosis in patients with stage III-IV epithelial ovarian cancer. <i>International Journal of Clinical Oncology</i> , 2021, 26, 995-1004.	2.2	10
9	Human papillomavirus genotype contribution to cervical cancer and precancer: Implications for screening and vaccination in Japan. <i>Cancer Science</i> , 2020, 111, 2546-2557.	3.9	22
10	Ovarian Cancer Stemness: Biological and Clinical Implications for Metastasis and Chemotherapy Resistance. <i>Cancers</i> , 2019, 11, 907.	3.7	41
11	An evolving story of the metastatic voyage of ovarian cancer cells: cellular and molecular orchestration of the adipose-rich metastatic microenvironment. <i>Oncogene</i> , 2019, 38, 2885-2898.	5.9	135
12	Radical resection of an endometrioid carcinoma arising from endometriosis in the round ligament within the right canal of Nuck: a case report and literature review. <i>Gynecologic Oncology Reports</i> , 2018, 24, 61-64.	0.6	10
13	Emerging Role of CD44 Variant 6 in Driving the Metastatic Journey of Ovarian Cancer Stem Cells. , 2018, , 73-88.		0
14	The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer. <i>Oncotarget</i> , 2017, 8, 44312-44325.	1.8	76
15	Genomics in Gynecological Cancer: Future Perspective. <i>Comprehensive Gynecology and Obstetrics</i> , 2017, , 9-21.	0.0	0
16	CD44 Variant 6 as a Predictive Biomarker for Distant Metastasis in Patients With Epithelial Ovarian Cancer. <i>Obstetrics and Gynecology</i> , 2016, 127, 1003-1011.	2.4	28
17	Hepatobiliary and Pancreatic: Rapid growing cystic ovarian metastasis from pancreatic cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 707-707.	2.8	5
18	Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche. <i>Cancer Cell</i> , 2016, 30, 273-289.	16.8	143

#	ARTICLE	IF	CITATIONS
19	Onionin A inhibits ovarian cancer progression by suppressing cancer cell proliferation and the protumour function of macrophages. <i>Scientific Reports</i> , 2016, 6, 29588.	3.3	42
20	CD 44 variant 6 is correlated with peritoneal dissemination and poor prognosis in patients with advanced epithelial ovarian cancer. <i>Cancer Science</i> , 2015, 106, 1421-1428.	3.9	77
21	Anti-N-methyl-d-aspartate receptor encephalitis associated with ovarian teratoma: clinical presentation, diagnosis, treatment, and surgical management. <i>International Cancer Conference Journal</i> , 2013, 2, 121-130.	0.5	2
22	xCT Inhibition Depletes CD44v-Expressing Tumor Cells That Are Resistant to EGFR-Targeted Therapy in Head and Neck Squamous Cell Carcinoma. <i>Cancer Research</i> , 2013, 73, 1855-1866.	0.9	163
23	Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell. <i>Nature Communications</i> , 2012, 3, 883.	12.8	324
24	CD44 Variant Regulates Redox Status in Cancer Cells by Stabilizing the xCT Subunit of System xc ⁺ and Thereby Promotes Tumor Growth. <i>Cancer Cell</i> , 2011, 19, 387-400.	16.8	1,020
25	Transient depletion of p53 followed by transduction of c-Myc and K-Ras converts ovarian stem-like cells into tumor-initiating cells. <i>Carcinogenesis</i> , 2011, 32, 1597-1606.	2.8	51
26	Long-term oncological outcomes of ovarian serous carcinomas with psammoma bodies: A novel insight into the molecular pathogenesis of ovarian epithelial carcinoma. <i>Cancer Science</i> , 2010, 101, 1550-1556.	3.9	27